BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35081851)

  • 1. Advances in the drug management of basal cell carcinoma.
    Ramelyte E; Restivo G; Mannino M; Levesque MP; Dummer R
    Expert Opin Pharmacother; 2022 Apr; 23(5):573-582. PubMed ID: 35081851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
    Jain R; Dubey SK; Singhvi G
    Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of basal cell carcinoma.
    Herms F; Basset-Seguin N
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):17-26. PubMed ID: 33412913
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
    Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
    Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the current and emerging pharmacotherapies for basal cell carcinomas.
    Villani A; Scalvenzi M; Micali G; Martora F; Cillo F; Raia F; Potestio L
    Expert Opin Pharmacother; 2023; 24(18):2143-2151. PubMed ID: 37963910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
    Zhu H; Lewis DJ
    Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
    Kudchadkar R; Lewis K; Gonzalez R
    Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging trends in the treatment of advanced basal cell carcinoma.
    Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
    Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
    Rudnick EW; Thareja S; Cherpelis B
    Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs and combination strategies for basal cell carcinoma.
    Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.